Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Craig Gower-Page"'
Autor:
Yusuke, Narita, Takuya, Yoshimoto, Tomoyuki, Namai, Takashi, Asakawa, Satoe, Kawakami, Craig, Gower-Page, Irmarie, Reyes-Rivera, Arisha, Patel, Yoshiaki, Nakamura
Publikováno v:
JCO clinical cancer informatics. 6
We compared overall survival (OS) in patients with human epidermal growth factor receptor 2 (A noninterventional study was conducted using patient-level data from MyPathway participants receiving PER-HER and real-world patients withThe PER-HER arm co
Autor:
Yusuke Narita, Takuya Yoshimoto, Tomoyuki Namai, Takashi Asakawa, Satoe Kawakami, Craig Gower-Page, Irmarie Reyes-Rivera, Arisha Patel, Yoshiaki Nakamura
Publikováno v:
JCO Clinical Cancer Informatics.
PURPOSE We compared overall survival (OS) in patients with human epidermal growth factor receptor 2 ( HER2)–amplified, treatment-refractory metastatic colorectal cancer (mCRC) receiving pertuzumab plus trastuzumab (PER-HER) in the phase IIa MyPathw
Autor:
Carsten Schröder, Craig Gower-Page, Irmarie Reyes-Rivera, Arisha Patel, Richard Price, Shiraj Sen, Jessica Davies, Emily Castellanos, Jeremy Snider, Xiaobo Bai, Virginia Fisher, Shivani K. Mhatre
Publikováno v:
JCO clinical cancer informatics. 6
PURPOSE The molecular heterogeneity of metastatic colorectal cancer (mCRC) presents a therapeutic challenge, with few trials focused on patients with human epidermal growth factor receptor 2 amplification (HER2-Amp). Our limited understanding of real
Publikováno v:
Journal of Open Source Software. 7:4251
Autor:
Takuya Yoshimoto, Yusuke Narita, Miho Yuki, Takashi Asakawa, Satoe Kawakami, Craig Gower-Page, Irmarie Reyes-Rivera, Arisha Patel, Yoshiaki Nakamura
Publikováno v:
Journal of Clinical Oncology. 40:36-36
36 Background: ML28897 (MyPathway) is a multi-basket trial evaluating the efficacy and safety of targeted therapies in non-indicated tumor types harboring relevant genetic alterations. In MyPathway, patients with treatment-refractory HER2-amplified m